We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+14.86%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$366M
AUM Growth
+$56.4M
Cap. Flow
+$27.5M
Cap. Flow %
7.51%
Top 10 Hldgs %
57.01%
Holding
57
New
4
Increased
13
Reduced
4
Closed
5
Avg Time Held
2 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
1.6 years

Top Buys

Rank Stock Value
1
CCXI icon
ChemoCentryx, Inc.
CCXI
+$13.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.76M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$8.6M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.46M
5
AMGN icon
Amgen
AMGN
+$6.46M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.1M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$8.98M
3
IMMU
Immunomedics Inc
IMMU
+$4.22M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.45M
5
BIIB icon
Biogen
BIIB
+$2.79M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
2 Miscellaneous 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$32.5M 8.87%
444,000
+55,000
+14% +$4.09M
2016 Q4
16 quarters
ACAD icon
2
Acadia Pharmaceuticals
ACAD
$3.29B
$26M 7.1%
486,000
– –
2018 Q3
9 quarters
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$127B
$23M 6.28%
97,322
+32,500
+50% +$7.46M
2016 Q4
16 quarters
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$10.6B
$21.7M 5.92%
247,584
– –
2016 Q4
16 quarters
PTCT icon
5
PTC Therapeutics
PTCT
$4.94B
$20.3M 5.55%
333,000
+34,000
+11% +$2M
2019 Q1
7 quarters
GILD icon
6
Gilead Sciences
GILD
$194B
$20.3M 5.54%
348,284
+27,000
+8% +$1.63M
2016 Q4
16 quarters
BHVN icon
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$17.2M 4.69%
200,400
+63,000
+46% +$5.34M
2020 Q2
2 quarters
AMGN icon
8
Amgen
AMGN
$234B
$16.5M 4.52%
72,000
+28,000
+64% +$6.46M
2018 Q4
8 quarters
CCXI icon
9
DELISTED
ChemoCentryx, Inc.
CCXI
$15.8M 4.31%
255,600
+232,000
+983% +$13.3M
2020 Q1
3 quarters
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$15.5M 4.23%
99,241
+24,000
+32% +$3.08M
2016 Q4
16 quarters
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$14.8M 4.04%
67,400
+40,500
+151% +$8.76M
2019 Q1
7 quarters
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$13.8M 3.77%
113,541
+78,541
+224% +$8.6M
2019 Q4
4 quarters
HALO icon
13
Halozyme
HALO
$13.8B
$13.1M 3.59%
307,633
– –
2016 Q4
16 quarters
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
$11.5M 3.13%
65,500
– –
2017 Q1
15 quarters
EXEL icon
15
Exelixis
EXEL
$15.4B
$10.6M 2.89%
526,534
– –
2016 Q4
16 quarters
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$9.06M 2.48%
71,000
– –
2019 Q1
7 quarters
BIIB icon
17
Biogen
BIIB
$34.4B
$8.02M 2.19%
32,800
-10,800
-25% -$2.79M
2018 Q4
8 quarters
INCY icon
18
Incyte
INCY
$22.9B
$6.78M 1.85%
78,000
– –
2016 Q4
16 quarters
REGN icon
19
Regeneron Pharmaceuticals
REGN
$81.4B
$5.55M 1.52%
11,500
– –
2020 Q2
2 quarters
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.81B
$5.36M 1.47%
31,500
– –
2017 Q2
14 quarters
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$31B
$4.72M 1.29%
36,300
– –
2017 Q3
13 quarters
IONS icon
22
Ionis Pharmaceuticals
IONS
$7.14B
$4.4M 1.2%
77,781
+38,000
+96% +$1.89M
2017 Q1
15 quarters
KALV icon
23
DELISTED
KalVista Pharmaceuticals
KALV
$3.37M 0.92%
177,433
– –
2016 Q4
16 quarters
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.76B
$3.37M 0.92%
22,000
– –
2019 Q4
4 quarters
PTGX icon
25
Protagonist Therapeutics
PTGX
$8.33B
$3.06M 0.84%
152,000
– –
2020 Q3
1 quarter
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2020 Portfolio in Review

As of Q4 2020, International Biotechnology Trust held 57 positions worth $366M, up 18% from $310M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust deployed $27.5M of net new capital in Q4 2020, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 53,000 shares worth $1.79M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.1M trimmed.

  • International Biotechnology Trust's largest Q4 2020 buy was Oric Pharmaceuticals: 53,000 shares worth $1.79M.
  • International Biotechnology Trust added most to ChemoCentryx, Inc. in Q4 2020, an estimated $13.3M increase.
  • International Biotechnology Trust's biggest Q4 2020 reduction was Neurocrine Biosciences, cutting an estimated $19.1M.
  • International Biotechnology Trust fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $8.98M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $366M portfolio in Q4 2020.
  • International Biotechnology Trust opened 4 new positions and closed 5 in Q4 2020.
  • International Biotechnology Trust's portfolio value rose 18% quarter-over-quarter to $366M.

Based on International Biotechnology Trust's 13F filing for Q4 2020, filed 19 Feb 2021.